Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,755.20
(
-1.56%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
108.37
(
1.68%
)
Bitcoin
71,156.63
(
-0.12%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

mcbio

Send PM Follow Ignore
Followers 69
Posts 6152
Boards Moderated 0
Alias Born 11/26/2008

mcbio

Re: DonShimoda post# 157508

Tuesday, 02/26/2013 7:49:03 PM

Tuesday, February 26, 2013 7:49:03 PM

Post# of 257257

Based on discussions with the FDA, the company feels an NDA can be filed with results from any two of the three Ph3 trials.

One more follow-up if I may. Are you saying XOMA has to hit on 2 of the 3 Phase 3 trials for approval? So, positive results in Eyeguard B won't be sufficient for approval if the two prior trials fail beforehand?
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now